Muramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors
Alzheimer’s disease (AD) is the most common form of dementia in the world. The prevalence is steadily increasing due to an aging population and the lack of effective treatments. However, modulation of innate immune cells is a new therapeutic avenue, which is quite effective at delaying disease onset...
Main Authors: | Pierre-Alexandre Piec, Vincent Pons, Paul Préfontaine, Serge Rivest |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/14/2241 |
Similar Items
-
Triggering Innate Immune Receptors as New Therapies in Alzheimer’s Disease and Multiple Sclerosis
by: Pierre-Alexandre Piec, et al.
Published: (2021-08-01) -
Regulation of Immune Homeostasis via Muramyl Peptides-Low Molecular Weight Bioregulators of Bacterial Origin
by: Svetlana V. Guryanova
Published: (2022-07-01) -
The Role of the Bacterial Muramyl Dipeptide in the Regulation of GLP-1 and Glycemia
by: Laura Williams, et al.
Published: (2020-07-01) -
Effect of muramyl dipeptide and alum adjuvants on immunization with Filarial multi antigen peptide vaccine in mice model
by: Christiana I., et al.
Published: (2016-09-01) -
The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer’s Disease Treatment
by: Majid Ghareghani, et al.
Published: (2023-06-01)